Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines

被引:29
作者
Bradshaw, Tracey D. [1 ]
Stone, Erica L. [1 ]
Trapani, Valentina [1 ]
Leong, Chee-Onn [1 ]
Matthews, Charles S. [1 ]
Poele, Robert te [2 ]
Stevens, Malcolm F. G. [1 ]
机构
[1] Univ Nottingham, Ctr Biomol Sci, Nottingham NG7 2RD, England
[2] Inst Canc Res, Surrey, England
关键词
breast cancer; benzothiazole; phortress; acquired resistance; aryl hydrocarbon receptor;
D O I
10.1007/s10549-007-9690-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Compounds within the 2-(4-aminophenyl)benzothiazole class represent extremely potent and selective experimental antitumour agents. The lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole is undergoing phase I clinical evaluation. Extensive studies to elucidate mechanisms underlying the stark selectivity demonstrated potent cytosolic AhR ligand binding and cytochrome P450 1A1-catalysed bioactivation. Two human derived breast cell lines, initially exquisitely sensitive to this class of agent (GI(50) < 5 nM) have been derived displaying acquired resistance to 2-(4-amino-3-methylphenyl)benzothiazole (DF 203; GI(50) > 50 mu M). Cross resistance to 2-(4-amino-3-iodophenyl)benzothiazole and 2-(4-amino-3-cyanophenyl)benzothiazole is observed (GI(50) > 30 mu M) as is > 100-fold reduced sensitivity of the two variant lines to 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203). In contrast, cell lines possessing acquired resistance to DF 203 (203R) retain sensitivity to benzo[a]pyrene and doxorubicin. Examination of DF 203-treated cells by confocal microscopy and HPLC analyses of nutrient media concur revealing diminished depletion of DF 203 from medium and impaired intracellular DF 203 retention. In contrast to cytosolic arylhydrocarbon (AhR) receptors of wild type cells, AhR appears constitutively localised within nuclei of 203R cells; consequently, DF 203 fails to drive transcription of cyp1a1. DF 203- and 5F 203-derived DNA adducts fall significantly in 203R cells. Reduced number and intensity of gamma H2AX foci report protection against DF 203-evoked DNA double strand breaks. In conclusion, aberrant AhR signalling underlies at least in part acquired resistance to DF 203. Intriguingly, comparisons of gene transcription profiles between sensitive and resistant paired lines reveal > 5-fold up-regulation of cyp1b1 expression, a protein implicated in resistance to therapeutic agents.
引用
收藏
页码:57 / 68
页数:12
相关论文
共 34 条
  • [1] AKMAN SA, 1990, CANCER RES, V50, P1397
  • [2] Proteasomal degradation of human CYP1B1: Effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression
    Bandiera, S
    Weidlich, S
    Harth, V
    Broede, P
    Friedberg, T
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (02) : 435 - 443
  • [3] CROSS-COUPLING OF SIGNAL TRANSDUCTION PATHWAYS - THE DIOXIN RECEPTOR MEDIATES INDUCTION OF CYTOCHROME P-450IA1 EXPRESSION VIA A PROTEIN KINASE-C-DEPENDENT MECHANISM
    BERGHARD, A
    GRADIN, K
    PONGRATZ, I
    WHITELAW, M
    POELLINGER, L
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) : 677 - 689
  • [4] The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate
    Bradshaw, TD
    Westwell, AD
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (08) : 1009 - 1021
  • [5] In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles
    Bradshaw, TD
    Chua, MS
    Browne, HL
    Trapani, V
    Sausville, EA
    Stevens, MFG
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (08) : 1348 - 1354
  • [6] Bradshaw TD, 2002, MOL CANCER THER, V1, P239
  • [7] 2-(4-aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity
    Bradshaw, TD
    Wrigley, S
    Shi, DF
    Schultz, RJ
    Paull, KD
    Stevens, MFG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (05) : 745 - 752
  • [8] Chua MS, 2000, CANCER RES, V60, P5196
  • [9] Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential
    Clarke, PA
    Poele, RT
    Wooster, R
    Workman, P
    [J]. BIOCHEMICAL PHARMACOLOGY, 2001, 62 (10) : 1311 - 1336
  • [10] COWAN KH, 1982, J BIOL CHEM, V257, P5079